LabCorp/Myriad Genetics
This article was originally published in The Gray Sheet
Executive Summary
Myriad predictive medicine products, including the BracAnalysis test for assessing a woman's risk of developing breast or ovarian cancer, will be distributed by LabCorp's 600-rep U.S. sales force in addition to Myriad's 85-person oncology sales force, under an exclusive marketing alliance announced Dec. 4...
You may also be interested in...
Myriad Genetics DTC Ads For BRACAnalysis To Focus On Prevention Market
Myriad Genetics will concentrate direct-to-consumer advertising in Atlanta and Denver for its BRACAnalysis breast and ovarian cancer genetic predisposition testing service as the firm moves beyond physician education as a sole means of promotion
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.